NAMS · NewAmsterdam Pharma Co N.V.
$26.85
-1.02 (-3.66%)
At close · Aug 24
Market Cap
$3.33B
Shares
119.54M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$22.5M
-50.6%
FY2025
Net Income
-$203.82M
+15.6%
FY2025
Operating Margin
-1002.9%
-616pp
FY2025
Diluted EPS
-$1.72
+32.8%
FY2025
Operating Cash Flow
-$147.78M
+6.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $7.12M | $22.5M | $45.56M | $14.09M | $102.69M | — | — | |
| $149.25M | $141.83M | $151.41M | $159.42M | $86.74M | $28.97M | — | |
| $13.33M | $15.37M | $14.44M | $16.32M | $13.59M | — | — | |
| $102.28M | $106.35M | $70.45M | $37.63M | $19.51M | $6M | — | |
| $212K | $220K | $113K | $49K | $9000 | $5000 | — | |
| $251.53M | $248.19M | $221.85M | $197.06M | $106.25M | $34.98M | — | |
| -$244.41M | -$225.68M | -$176.29M | -$182.97M | -$3.56M | -$34.98M | — | |
| — | -1002.9% | -386.91% | -1298.56% | -3.46% | — | — | |
| -$244.2M | -$225.46M | -$176.18M | -$182.92M | -$3.55M | -$34.97M | — | |
| — | — | — | — | $287K | $411K | — | |
| $24.65M | $27.59M | $16.88M | $11.28M | — | — | — | |
| -$259.5M | -$203.82M | -$241.6M | -$176.91M | -$22.63M | -$41.79M | — | |
| — | — | -$1000 | $27K | — | — | — | |
| -$258.69M | -$203.82M | -$241.6M | -$176.94M | -$22.63M | -$41.79M | -$5.75M | |
| — | -905.74% | -530.25% | -1255.76% | -22.04% | — | — | |
| -$259.97M | -$203.49M | -$241.55M | -$176.94M | -$11.51M | -$41.5M | — | |
| USD/shares | — | -$1.72 | -$2.56 | -$2.15 | -$1.19 | -$3.81 | — |
| USD/shares | — | -$1.72 | -$2.56 | -$2.15 | -$1.19 | -$3.81 | — |
| shares | — | 118.42M | 94.36M | 82.16M | 18.97M | 10.98M | — |
| shares | — | 118.42M | 94.36M | 82.16M | 18.97M | 10.98M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 6.96×
EV/EBIT
—
Peer median 16.92×
P/E (TTM)
—
Peer median 17.88×
Peer medians compare against the 223 similar-size Biotechnology companies (of 517 listed).
Key facts
CIK
1936258
CUSIP
N62509109
13F (30d)
180 filings
176 filers
Visit website
Investor relations